(HeadStart 4) Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue

Purpose

This research study will compare two different treatment regimens to see which is better for treating children with different types of brain tumors called medulloblastoma and CNS embryonal tumors of the brain or spinal cord.

Eligibility 

  • 0 - 10 years old 
  • Disease: Brain tumor
  • Disease type: Medulloblastoma, Central Nervous System Embryonal Tumors

For additional information about eligibility criteria, please contact the study coordinator Jennifer King:

Procedures

  • Drug: Induction
  • Drug type: Chemotherapy

For additional information about study procedures, please contact the study coordinator Jennifer King:

Gender

Male
Female

Keywords

Brain tumor - children, Central nervous system, Tumor, chemotherapy

Principal Investigator

Sridharan Gururangan

Department

MD-NEUROLOGICAL SURGERY

Contact Information

jennifer.king@neurosurgery.ufl.edu

352.294.8374

Begin a new search for other research studies

Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at UFStudies@health.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams